This clinical trial is focused on studying a type of cancer known as colorectal cancer, specifically in cases where the cancer has returned, cannot be surgically removed, or has spread to other parts of the body. The study is particularly interested in patients whose cancer does not have certain genetic mutations, specifically KRAS, NRAS, and BRAF wild-type mutations. The trial will explore the effectiveness of a new treatment combination involving a medication called Amivantamab and a chemotherapy regimen known as FOLFIRI, compared to another treatment combination using Cetuximab or Bevacizumab with FOLFIRI.
The purpose of the study is to compare how well these treatment combinations work in controlling the cancer. Participants will receive one of the treatment combinations and will be monitored over time to see how their cancer responds. The study will involve regular visits to the clinic for treatment and assessments, which will include various tests to check the progress of the cancer and the overall health of the participants.
Throughout the study, participants will receive their treatments through an infusion, which means the medication will be given directly into a vein. The study aims to provide valuable information on which treatment combination might be more effective for patients with this specific type of colorectal cancer. The trial will continue until enough information is gathered to make a clear comparison between the two treatment options.
Belgium 
France 
Germany 
Hungary 
Italy 
Poland 
Romania 
Spain 
Sweden 
The Netherlands 
